Jorge L Alió1, Felipe Soria2, Alessandro Abbouda2, Pablo Peña-García2. 1. From Vissum Instituto Oftalmologico de Alicante (Alió, Soria, Abbouda) and the Division of Ophthalmology (Alió, Peña-García), Universidad Miguel Hernández, Alicante, Spain. Electronic address: jlalio@vissum.com. 2. From Vissum Instituto Oftalmologico de Alicante (Alió, Soria, Abbouda) and the Division of Ophthalmology (Alió, Peña-García), Universidad Miguel Hernández, Alicante, Spain.
Abstract
PURPOSE: To evaluate the long-term outcomes of laser in situ keratomileusis (LASIK) for high myopia with or without astigmatism. SETTING: Vissum Instituto Oftalmologico de Alicante and Miguel Hernandez University, Alicante, Spain. DESIGN: Retrospective-prospective case series. METHODS: Laser in situ keratomileusis was performed using the Visx 20/20 excimer laser. The minimum follow-up was 15 years. The main outcome measures were uncorrected (UDVA) and corrected (CDVA) distance visual acuities, manifest refraction, and corneal topography. RESULTS: This study included 40 patients (40 eyes) with a mean age of 51.08 years ± 6.67 (SD) (range 41 to 60 years) with high myopia (-6.00 to -18.00 diopters [D]). At 15 years, the safety index was 1.23 and the efficacy index, 0.95. During the follow-up, a significant increase in the dioptric power of all keratometric variables was detected (P≤.028, Friedman test), the most notable increase occurring between 3 months and 1 year (P≤.005). At 15 years, 46.15% of the eyes were within ±1.00 D of the attempted spherical equivalent and 64.10% were within ±2.00 D. The UDVA at 15 years was 20/25 or better in 43.59% of eyes and 20/40 or better in 64.10% of eyes. The postoperative CDVA was significantly better than preoperatively (P<.001). The postoperative complications were minor except in 1 eye in which ectasia occurred. CONCLUSIONS: Laser in situ keratomileusis for high myopia was safe over the long term. However, significant myopic regression with time was detected. Low preoperative pachymetry and low residual stromal bed were predictors of keratometric regression. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.
PURPOSE: To evaluate the long-term outcomes of laser in situ keratomileusis (LASIK) for high myopia with or without astigmatism. SETTING: Vissum Instituto Oftalmologico de Alicante and Miguel Hernandez University, Alicante, Spain. DESIGN: Retrospective-prospective case series. METHODS: Laser in situ keratomileusis was performed using the Visx 20/20 excimer laser. The minimum follow-up was 15 years. The main outcome measures were uncorrected (UDVA) and corrected (CDVA) distance visual acuities, manifest refraction, and corneal topography. RESULTS: This study included 40 patients (40 eyes) with a mean age of 51.08 years ± 6.67 (SD) (range 41 to 60 years) with high myopia (-6.00 to -18.00 diopters [D]). At 15 years, the safety index was 1.23 and the efficacy index, 0.95. During the follow-up, a significant increase in the dioptric power of all keratometric variables was detected (P≤.028, Friedman test), the most notable increase occurring between 3 months and 1 year (P≤.005). At 15 years, 46.15% of the eyes were within ±1.00 D of the attempted spherical equivalent and 64.10% were within ±2.00 D. The UDVA at 15 years was 20/25 or better in 43.59% of eyes and 20/40 or better in 64.10% of eyes. The postoperative CDVA was significantly better than preoperatively (P<.001). The postoperative complications were minor except in 1 eye in which ectasia occurred. CONCLUSIONS: Laser in situ keratomileusis for high myopia was safe over the long term. However, significant myopic regression with time was detected. Low preoperative pachymetry and low residual stromal bed were predictors of keratometric regression. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.
Authors: Virgilio Galvis; John F Villamil; María Fernanda Acuña; Paul A Camacho; Jesús Merayo-Lloves; Alejandro Tello; Sandra Lizeth Zambrano; Juan José Rey; Juan Vicente Espinoza; Angélica María Prada Journal: Graefes Arch Clin Exp Ophthalmol Date: 2019-10-28 Impact factor: 3.117